Atara Biotherapeutics, Inc.ATRANASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P0
Near historical low
vs 5Y Ago
-9.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -91.99% |
| Q3 2025 | -60.19% |
| Q2 2025 | -73.35% |
| Q1 2025 | -4.48% |
| Q4 2024 | -34.61% |
| Q3 2024 | 31.78% |
| Q2 2024 | -26.75% |
| Q1 2024 | 3.47% |
| Q4 2023 | -22.69% |
| Q3 2023 | 1.33% |
| Q2 2023 | -9.68% |
| Q1 2023 | -0.57% |
| Q4 2022 | -10.89% |
| Q3 2022 | 8.10% |
| Q2 2022 | -13.43% |
| Q1 2022 | -5.27% |
| Q4 2021 | 12.51% |
| Q3 2021 | 2.71% |
| Q2 2021 | 6.89% |
| Q1 2021 | -2.28% |
| Q4 2020 | 9.48% |
| Q3 2020 | -2.73% |
| Q2 2020 | 6.77% |
| Q1 2020 | -6.46% |
| Q4 2019 | 15.13% |
| Q3 2019 | 2.46% |
| Q2 2019 | 7.36% |
| Q1 2019 | -21.82% |
| Q4 2018 | 43.59% |
| Q3 2018 | 29.86% |
| Q2 2018 | 17.31% |
| Q1 2018 | 14.89% |
| Q4 2017 | 20.26% |
| Q3 2017 | 12.58% |
| Q2 2017 | 4.30% |
| Q1 2017 | 30.18% |
| Q4 2016 | -28.34% |
| Q3 2016 | 44.73% |
| Q2 2016 | 15.51% |
| Q1 2016 | -45.75% |